Should you buy Arcturus Therapeutics stock now?
The technical signal for Arcturus Therapeutics is currently NEUTRAL. Arcturus Therapeutics trades at $0.00 as of 8/24/2026. The overall technical signal is: Hold. The technical analysis shows the following: MACD is positive (bullish trend) at 1.168 with rising momentum (signal: 0.526); RSI is at 89.5 (overbought), suggesting the price may have risen too quickly. This is a technical observation based on current data, not investment advice.
What is the price target for Arcturus Therapeutics stock?
There is currently no active analyst price target for Arcturus Therapeutics.
Is Arcturus Therapeutics a dividend stock?
No, Arcturus Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Arcturus Therapeutics stock?
Arcturus Therapeutics is rated as a stock in the risk category Extremely speculative. the annual standard deviation is 90.2%, which classifies the stock as Extremely speculative. In addition, an RSI of 89.5 signals overbought (elevated risk of a pullback).
Is Arcturus Therapeutics overvalued?
Arcturus Therapeutics has the following valuation ratios: a P/S ratio of 13.0, a P/B ratio of 2.2.
Is Arcturus Therapeutics overbought?
Yes, Arcturus Therapeutics is overbought with an RSI of 89.5 (above 70). The technical indicators show: RSI is at 89.5 (above the 70 mark), which signals the price is overbought and may have risen too quickly. In addition, MACD is positive with rising momentum (bullish).
When is the next Arcturus Therapeutics earnings report?
The date of the next earnings report for Arcturus Therapeutics has not been published yet. Check the company's investor calendar for updates.
Is Arcturus Therapeutics shorted?
Yes, Arcturus Therapeutics is shorted with 31.5% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. Data is updated daily based on official filings with the SEC.
Are insiders buying Arcturus Therapeutics stock?
No, insiders are not buying Arcturus Therapeutics shares – they are net sellers. Across the last 20 reported transactions, the split is 1 purchases and 19 sales, with a net 6,582,058 $ sold. Active sellers include SASSINE ANDY, Chivukula Pad, Kummerfeld Keith C. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Arcturus Therapeutics a good stock?
Based on our total score, Arcturus Therapeutics is rated as a poor stock with a total score of 23 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 20/100, Quality: 8/100, Momentum: 41/100. In addition: technical signal: Hold. Whether Arcturus Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Arcturus Therapeutics stock?
The outlook for Arcturus Therapeutics based on current data: Detailed data is currently not available. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Arcturus Therapeutics stock moving?
Arcturus Therapeutics is moving right now. The technical indicators show: MACD is positive with rising momentum (bullish signal); short interest is 31.5% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Arcturus Therapeutics go?
There is currently no active analyst price target for Arcturus Therapeutics. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Arcturus Therapeutics fall?
We lack enough history to give a specific floor for Arcturus Therapeutics. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Arcturus Therapeutics do?
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery syste... The company belongs to the Healthcare sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Arcturus Therapeutics as an investment.
Did Arcturus Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Arcturus Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Arcturus Therapeutics making money or losing money?
We have no current profitability data for Arcturus Therapeutics. See the latest report in the earnings history above.
Can Arcturus Therapeutics go bankrupt?
The bankruptcy risk of Arcturus Therapeutics is rated as elevated. Altman Z2 (a model for assessing financial distress) is -2.10 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 1 — which is weak. Debt relative to equity is 43% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Arcturus Therapeutics have a lot of debt?
No, Arcturus Therapeutics has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 43%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
